^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IL2 expression

i
Other names: IL2, IL-2, TCGF, Interleukin 2
Entrez ID:
Related biomarkers:
11d
Paeoniflorin Attenuates Oxidative Stress and Inflammation in Parkinson's Disease by Activating the HSF1-NRF1 Axis. (PubMed, Am J Chin Med)
These effects were neutralized by HSF1 knockdown. In conclusion, PF dose-dependently activated the HSF1-NRF1 axis and alleviated OS and inflammation in PFF-treated mice, thereby impeding PD progression in mice.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CASP8 (Caspase 8) • NRF1 (Nuclear Respiratory Factor 1) • BDNF (Brain Derived Neurotrophic Factor) • CAT (Catalase) • HSF1 (Heat Shock Transcription Factor 1)
|
IL10 elevation • IL2 expression • IL6 expression • NRF1 expression
14d
Effect of hypoxia-induced mIL15 expression on expansion and memory progenitor stem-like TILs in vitro. (PubMed, Front Immunol)
Furthermore, compared to UN-TIL and TIL-mIL15+IL2 cells, TIL-mIL15-IL2 cells showed significantly lower expression levels of inhibitory receptors LAG3, TIGIT, and TIM3, which was consistent with the RNA-Seq results. This study demonstrates the superior persistence of TIL-mIL15-IL2 cells, which may serve as a novel treatment strategy for lung cancer patients.
Preclinical • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • PRDM1 (PR/SET Domain 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • IL15 (Interleukin 15) • TCF7 (Transcription Factor 7)
|
LAG3 expression • IL2 expression
18d
Effect of Prednisolone on Clinical and Cytokine mRNA Profiling in Complex Regional Pain Syndrome. (PubMed, J Mol Neurosci)
None had to be withdrawn due to severe side effects. Future study in larger cohort may validate these findings.
Clinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
|
IL2 expression
1m
Arachidonic acid impairs natural killer cell functions by disrupting signaling pathways driven by activating receptors and reactive oxygen species. (PubMed, Cell Commun Signal)
Our findings highlight significant AA-induced alterations in the signaling network that regulates NK cell activity. As low expression of several NK cell receptors correlates with shorter OC patient survival, these findings suggest a functional linkage between AA, NK cell dysfunction and OC progression.
Journal
|
IL2 (Interleukin 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • STAT1 (Signal Transducer And Activator Of Transcription 1) • NKG2D (killer cell lectin like receptor K1)
|
IL2 expression
1m
Expression of Immune Checkpoint Regulator Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) and Programmed Cell Death Protein Ligand 1 (PD-L1) in Invasive Ductal Carcinoma Breast. (PubMed, Indian J Surg Oncol)
Our study shows that CTLA-4 is a more important immune checkpoint regulator in breast carcinomas in comparison to PD-L1. Thus, anti-CTLA-4 immunotherapy might prove to be of immense help in the treatment of invasive ductal carcinoma breast showing overexpression of CTLA-4.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • CTLA4 expression • CTLA4 underexpression • IL2 expression • PD-L1 expression + CTLA4 expression
1m
Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors. (PubMed, Pharmacol Res)
Mechanically, NKG7 preserved surface CAR expression and promoted CAR-T cell proliferation after exposing to relative tumor antigen. These results indicated that it may be feasible to explore single-cell sequencing data of clinical tumor samples to find strategies to improve CAR-T function, and that ectopic expression of NKG7 is an effective strategy to improve the therapeutic efficacy of CAR-T cells against tumors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD276 (CD276 Molecule) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • NKG7 (Natural Killer Cell Granule Protein 7)
|
CD19 expression • IL2 expression
1m
A Pump-Free Microfluidic Co-Culture System for Investigating NK Cell-Tumor Spheroid Interactions in Flow Conditions. (PubMed, J Biotechnol)
These findings suggest that tumor cells and fluid dynamics significantly influence NK cell subtypes. This pump-free microfluidic platform is a functional tool for simulating and studying immune cell-tumor interactions, providing valuable insights into NK cell dynamics with tumor spheroids in physiologically relevant environments.
Journal • IO biomarker
|
NCAM1 (Neural cell adhesion molecule 1)
|
IL2 expression
1m
Analysis of clinical characteristics and risk factors for recurrence of combined EB virus infection in patients with inflammatory bowel disease treated with biological agents (PubMed, Zhonghua Yu Fang Yi Xue Za Zhi)
The median age at 50 years of patients treated with Vedolizumab (VDZ) in the UC group was higher than in the treatment groups other than VDZ. The highest rate of EB virusreactivation was found in the group treated with immunosuppressants Azathioprine (AZA) combined with anti-tumor necrosis factor-α (anti-TNF-α) and VDZ (62.5% in both groups), and the lowest in the group treated with Ustekinumab (UST) (0%)...The AUC for IL-6 combined with EB virus in a replicative state was 0.900 (P<0.000 1), with negative and positive predictive value of 84.09% and 73.33%, respectively. In summary, the imbalance of proinflammatory and anti-inflammatory cytokines varies between drugs, with EBV in a replication-activated state, combined with elevated levels of IL-2 as well as IL-6 expression being a risk factor for relapse in patients treated with anti-TNF-α-related drugs and VDZ.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL10 (Interleukin 10) • CALR (Calreticulin) • IL17A (Interleukin 17A) • IL4 (Interleukin 4) • CRP (C-reactive protein)
|
IL2 elevation • IL2 expression • IL6 expression
|
Entyvio (vedolizumab)
1m
Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells. (PubMed, Front Immunol)
Finally, the CIK cell platform can be adapted for chimeric antigen receptor (CAR) cell strategy, showing promising results in both preclinical and clinical settings. In this review, we describe the main immunological basis for the development of the GvL and the possible cellular therapy approaches used to boost it, with a particular focus on the use of CIK cells.
Review • Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1)
|
IL2 expression
1m
Chemical analysis, antibacterial and anti-inflammatory effect of Achillea fragrantissima essential oil growing wild in Egypt. (PubMed, BMC Complement Med Ther)
A. fragrantissima EO is rich in oxygenated volatile compounds with antibacterial and anti-inflammatory activities. It is encouraged as a bioactive agent for adjusting skin infections, though additional studies are essential for their safety in clinical settings.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
IL2 expression • IL6 expression
2ms
Immune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia. (PubMed, Ann Hematol)
Univariate and multivariate analyses showed heightened ARG1 levels and a transition from PD1/PDL1 dominance at 3 months to TIM3/GAL9 at 12 months in non-optimal responders (BCR::ABL1 ≥ 0.1%). Our longitudinal design offers a deeper exploration of immune gene expression dynamics in CML patients on imatinib, highlighting its potential implications for therapy outcomes.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ABL1 (ABL proto-oncogene 1) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2 (Interleukin 2) • FOXP3 (Forkhead Box P3) • GATA3 (GATA binding protein 3) • IL4 (Interleukin 4)
|
IL2 expression • FOXP3 expression
|
imatinib
2ms
Enumeration and gentle sorting of immune cells on chip, key to next generation advanced therapies in outpatient setting. (PubMed, Cytotherapy)
Our technology allows for the development of a compact system which sets it apart from other efforts intended to create automated cell therapeutic solutions.
Journal • Metastases • Immune cell
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2) • CD14 (CD14 Molecule)
|
IL2 expression
2ms
Conditioned media from human adipose tissue-derived mesenchymal stem cells: potential effect on peripheral blood mononuclear cells in co-culture with HeLa cell line. (PubMed, Cytotechnology)
This observation indicates their promising potential as immunomodulatory therapies for cervical cancer cells. Nevertheless, additional investigation is imperative to comprehensively comprehend the fundamental mechanisms and refine therapeutic strategies involving PBMCs and mesenchymal stem cells.
Preclinical • Journal
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2) • TGFB1 (Transforming Growth Factor Beta 1)
|
IFNG expression • IL2 expression
2ms
Enhanced Wound Healing With β-Chitosan-Zinc Oxide Nanoparticles: Insights From Zebrafish Models. (PubMed, Cureus)
β-chitosan-derived zinc oxide nanoparticles show promising potential as a novel therapeutic strategy for enhancing wound healing. The synergistic effects of β-chitosan and zinc oxide nanoparticles address multiple aspects of wound healing, including antimicrobial activity, inflammation modulation, and tissue regeneration. This study highlights the advantages of nanotechnology in wound care and underscores the need for further research to optimize nanoparticle formulations for clinical applications.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression • IL2 expression
2ms
Hypothetical proteins of chicken-isolated Limosilactobacillus reuteri subjected to in silico analyses induce IL-2 and IL-10. (PubMed, Genes Nutr)
The evaluated mutants are IL-2 and IL-10-inducers but QHPv.2.13 and QHPv.2.15 are not immunogenic. This study sheds light on understanding the functional mechanisms of chicken-isolated L. reuteri and suggests it or its proteins as potent candidates for feed additive and therapeutic purposes.
Journal
|
IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
IL2 expression
2ms
Study on PINK1 Expression and Its Clinical Value in Diabetic Nephropathy. (PubMed, Iran J Kidney Dis)
PINK1 exhibits low expression levels in patients with diabetic nephropathy and its expression is strongly associated with the inhibition of disease progression, thereby offering significant clinical diagnostic value. Additionally, it may serve as a potential biological marker for clinical diagnosis and treatment of diabetic nephropathy.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • PINK1 (PTEN Induced Kinase 1)
|
IL2 expression
|
metformin
2ms
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3)
|
IFNG expression • IL2 expression • IL6 expression
3ms
The expression and clinical significance of cytokines Th1, Th2, and Th17 in ovarian cancer. (PubMed, Am J Med Sci)
In peripheral blood from OC patients, the immune system was more dysregulated and immune cells produced more cytokines with contrasting actions. These data showed significant clinical implications for the diagnosis of OC.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
CXCL8 expression • IL2 expression • IL6 expression
3ms
Efficacy of Jasminum subtriplinerve Extract against 7,12-Dimethylbenz[a]anthracene-Induced Cancer in Mice. (PubMed, J Microbiol Biotechnol)
No abnormal parameters in blood were observed in the J. subtriplinerve treatment groups. These results suggest that J. subtriplinerve, when used as tea or a functional food, is nontoxic and has clear chemopreventive effects against breast cancer.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
IL2 elevation • IL2 expression
4ms
B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity Against Solid Tumors. (PubMed, Cancer Res)
Additionally, the B7-H3-CAR-Vδ1T cells exhibited a favorable safety profile. In conclusion, B7-H3-CAR-modified Vδ1T cells represent a promising strategy for treating solid tumors.
Journal
|
CD276 (CD276 Molecule) • IL2 (Interleukin 2)
|
IL2 expression
4ms
Causal relationships between inflammatory cytokines and myopia: an analysis of genetic and observational studies. (PubMed, Ann Med Surg (Lond))
IL-2 expression was notably upregulated in the vitreous of guinea pigs with experimentally induced FDM. Elevated levels of inflammatory factors, especially IL-2 and IL-2ra, have a potential causal relationship with myopia susceptibility, providing new insights into the pathogenesis of myopia.
Observational data • Journal • Causal relationship
|
IL2RA (Interleukin 2 receptor, alpha) • CRP (C-reactive protein)
|
IL2 expression
7ms
Neurobrucellosis (Brucella ceti) in striped dolphins (Stenella coeruleoalba): Immunohistochemical studies on immune response and neuroinflammation. (PubMed, Vet Pathol)
Our results showed that the inflammation and neuroinflammation in neurobrucellosis of striped dolphins mimic human neurobrucellosis and in vitro and in vivo studies in laboratory animals. Cetacean disease surveillance can be exploited to expand the knowledge of the pathogenesis and immunology of infectious diseases, particularly brucellosis, under a One Health approach.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • FAP (Fibroblast activation protein, alpha) • GFAP (Glial Fibrillary Acidic Protein)
|
IFNG expression • IL2 expression
8ms
Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score. (PubMed, Cancer Immunol Immunother)
We found that all three TCRs in each patient could specifically identify corresponding ATCs. In conclusion, we established an efficient approach to isolate tumour-reactive TCRs based on combinations of multiple activation and effector molecules through single-cell RNA sequencing.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • GZMB (Granzyme B) • GZMA (Granzyme A) • GZMK (Granzyme K) • PRF1 (Perforin 1)
|
IFNG expression • IL2 expression
8ms
Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression. (PubMed, Front Immunol)
In particular, NKp30a overexpression in NK92 cells improved the clearance of THP-1 cells in vivo without IL-2 supplementation. Collectively, our results highlight the distinct role of IL-2 in the regulation of NKp30 compared to that of NKp46 and suggest NKp30 upregulation, as shown here by ectopic overexpression, as a viable modality to harness NK cells in cancer immunotherapy, possibly in combination with IL-2 immunocytokines.
Journal • IO biomarker
|
IL2 (Interleukin 2) • NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
IL2 expression
8ms
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. (PubMed, J Immunother Cancer)
Our findings illustrate that G47Δ-mIL2 is efficacious, stimulates antitumor immunity against orthotopic GBM, and may also target GSC. OHSV expressing IL-2 may represent an agent that merits further exploration in patients with GBM.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2)
|
IL2 expression
|
Imlygic (talimogene laherparepvec)
9ms
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production. (PubMed, Front Immunol)
These findings highlight the multifaceted roles of CD81 and CD82 in T cell activation, cytokine production, memory subset accumulation, and target cell cytolysis. Therefore, these findings suggest the potential of CD81 and CD82 as promising candidates for co-stimulatory molecules in immune therapeutic strategies for cancer treatment within the intricate TME.
Journal • Tumor-infiltrating lymphocyte
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • CD81 (CD81 Molecule)
|
CD8-H • IL2 expression
9ms
Immunoantitumor Activity and Oxygenation Effect Based on Iron-Copper-Doped Folic Acid Carbon Dots. (PubMed, ACS Appl Mater Interfaces)
Moreover, the observed downregulation of ARG1 expression indicates a transition in the tumor microenvironment from an immunosuppressive state to an antitumor state following treatment with CFCFB. The upregulation of IL-2 and CD8 expression facilitated the differentiation of effector T cells, resulting in an augmented population of CD8+ T cells, thereby indicating the activation of systemic immune response.
Journal
|
CD8 (cluster of differentiation 8) • CALR (Calreticulin)
|
CD8 expression • IL2 expression
9ms
Epstein-Barr Virus BRLF1 Induces PD-L1 Expression in Nasopharyngeal Carcinoma Cells. (PubMed, Viral Immunol)
We also demonstrated that Rta-induced PD-L1 expressions could impair interleukin 2 secretion of T cells, and this mechanism may be through ERK activation. These results displayed the importance of EBV Rta in PD-L1 expression in NPC and may give an alternative target for NPC therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IL2 (Interleukin 2)
|
PD-L1 expression • IL2 expression
9ms
IL-2/CD25 axis mediates cellular networks promoting the growth of CD25+ acute myeloid leukemia cells. (PubMed, Leuk Res Rep)
Since IL-2 can be trans-presented via CD25 to another cell, CD25+AML cells may deliver environmental IL-2 to surrounding immune cells to produce myeloid growth factors for their proliferation. We hypothesize that cellular interactions via IL-2/CD25 axis in the bone marrow microenvironment contributes to the growth advantage of these AML cells and affects the clinical outcome of those AML patients.
Journal
|
IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
IL2 expression
9ms
Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy. (PubMed, J Control Release)
Further evaluations indicated that the U-101-LNP/IL-2F mRNA group maintained proper levels of inflammatory factors without obvious alterations in liver and renal functions. Taken together, the U-101-LNP/IL-2F mRNA formulation demonstrated effective antitumor activity and safety, which suggests potential applicability in clinical immunotherapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • MMP14 (Matrix Metallopeptidase 14)
|
IFNG expression • IL2 expression
10ms
Predicting the mechanism of action of YQYYJD prescription in the treatment of non-small cell lung cancer using transcriptomics analysis. (PubMed, J Ethnopharmacol)
YQ was the key disassembled prescription of YQYYJD, exerting significant antitumor effects and immune regulation effects on NSCLC. It may have relieved T cell exhaustion and regulated the immune microenvironment to exert antitumor effects by changing lung cancer-related targets, pathways, and biological processes.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CASP3 (Caspase 3)
|
CD8 expression • IFNG expression • CD4 expression • IL2 expression
10ms
Three Artemisia pollens trigger the onset of allergic rhinitis via TLR4/MyD88 signaling pathway. (PubMed, Mol Biol Rep)
To sum up, the occurrence and development of AR induced by OVA and pollen of Artemisia annua, Artemisia argyi and Artemisia Sieversiana were related to TLR4/MyD88 signal pathway.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • TLR4 (Toll Like Receptor 4) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5) • RELA (RELA Proto-Oncogene)
|
IL2 expression
10ms
Study on the Effect and Mechanism of Tetrandrine on Bone Marrow Mesenchymal Stem Cell-Mediated Drug Resistance in Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
BMSC can promote the drug resistance of leukemia cells, and TET may reverse the BMSC-mediated drug resistance via inhibiting IL-6/STAT3 signaling pathway.
Journal
|
IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
IL2 expression • IL6 expression
|
daunorubicin • CBT-1 (tetrandrine)
10ms
Cytotoxic Programming of CD4+ T Cells Is Regulated by Opposing Actions of the Related Transcription Factors Eos and Aiolos. (PubMed, J Immunol)
Finally, we find that Aiolos, a related Ikaros family member and known CD4-CTL antagonist, represses Eos expression by antagonizing STAT5-dependent activation of the Ikzf4 promoter. Collectively, our findings reveal a mechanism wherein Eos and Aiolos act in opposition to regulate cytotoxic programming of CD4+ T cells.
Journal
|
CD8 (cluster of differentiation 8) • IKZF1 (IKAROS Family Zinc Finger 1) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL15 (Interleukin 15) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
IL2 expression
11ms
Effects of Lonicerae flos and Turmeric extracts on growth performance and intestinal health of yellow-feathered broilers. (PubMed, Poult Sci)
PICRUSt results showed that LTE300 was significantly (P < 0.05) enriched in four pathway pathways at KEGG level 2. In conclusion, dietary supplementation with LTE improved growth performance and intestinal health by enhancing antioxidant capacity, intestinal barrier and immune function, and regulating intestinal flora of yellow-feathered broilers.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • TLR4 (Toll Like Receptor 4) • CLDN1 (Claudin 1) • TJP1 (Tight Junction Protein 1) • OCLN (Occludin)
|
IL2 expression
|
chlorogenic acid
11ms
Janus kinase inhibitors modify the fatty acid profile of extracellular vesicles and modulate the immune response. (PubMed, Heliyon)
to evaluate the interactions between immune system components of healthy individuals and EVs derived from monocytic and lymphoid lineage cells generated in the presence of baricitinib (BARI) and itacitinib (ITA) and their possible effects. The higher proportion of arachidonic acid in the FA content of ITA-L/M-EVs could be related to the thrombosis described in patients treated with ITA. EVs also induced a decrease in the respiratory burst of neutrophils.
Journal
|
IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • IL2 (Interleukin 2)
|
IL2RA expression • IL2 expression
|
itacitinib (INCB039110)
11ms
Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis. (PubMed, Heliyon)
Additionally, in vitro experiments confirmed that PF reduces the expression of PD-L1 in Huh-7 liver cancer cells by inhibiting NF-κB. PF plays a synergistic role of Sor inhibiting HCC progression by regulating the NF-κB/PD-L1 pathway.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
PD-L1 expression • IFNG expression • IL2 expression
|
sorafenib
11ms
Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery. (PubMed, Mol Diagn Ther)
In summary, Clostridium species represent a promising platform for cancer therapy, with potential for localised gene delivery and immunomodulation selectively within the tumour microenvironment. The ongoing clinical progress being made with C. novyi-NT, in addition to developments in genetic modification techniques and non-invasive imaging capabilities, are expected to further progress Clostridium as an option for cancer treatment.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
IL2 expression
11ms
Multifunctional nanoparticles for enhanced sonodynamic-chemodynamic immunotherapy with glutathione depletion. (PubMed, Nanomedicine (Lond))
Both in vitro and in vivo experiments verified that AIPH/Cu-Cys@Lipo significantly inhibited tumor development by decreasing mitochondrial membrane potential, activating CD4 and CD8 T cells and promoting the expression of IL-2 and TNF-α. AIPH/Cu-Cys@Lipo provides high-quality strategies for safe and effective tumor immunotherapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
IL2 expression
12ms
Pien Tze Huang alleviates Concanavalin A-induced autoimmune hepatitis by regulating intestinal microbiota and memory regulatory T cells. (PubMed, World J Gastroenterol)
PTH regulates intestinal microbiota balance and restores mTreg cells to alleviate experimental AIH, which is closely related to the TLR/CXCL16/CXCR6/NF-κB signaling pathway.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • TLR4 (Toll Like Receptor 4) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • IL21 (Interleukin 21) • CXCL16 (C-X-C Motif Chemokine Ligand 16) • TLR2 (Toll Like Receptor 2)
|
IL2 expression • IL6 expression
1year
The lncRNA Malat1 inhibits miR-15/16 to enhance cytotoxic T cell activation and memory cell formation. (PubMed, Elife)
This study marks a significant advance in the study of long non-coding RNAs in the immune system by ascribing cell-intrinsic, sequence-specific in vivo function to Malat1. These findings have implications for T cell-mediated autoimmune diseases, antiviral and anti-tumor immunity, as well as lung adenocarcinoma and other malignancies where Malat1 is overexpressed.
Journal • IO biomarker
|
IL2 (Interleukin 2) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • AGO2 (Argonaute RISC Catalytic Component 2) • MIR15 (MicroRNA 15)
|
IL2 expression
1year
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
EGFR expression • EGFR overexpression • IL10 elevation • IL2 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210